Company Overview of Allozyne, Inc.
Allozyne, Inc., a biopharmaceutical company, provides novel protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases, and cancer. Its lead product candidate includes AZ01, a Phase 1b clinical trial product for the treatment of relapsing-remitting multiple sclerosis (RRMS). The company is also developing AZ17, a bispecific antibody for the treatment of various autoimmune and inflammatory diseases, including Crohn's disease and RRMS; and AZ05, an antibody-drug conjugate for the treatment of solid tumors. Allozyne, Inc. was founded in 2004 and is headquartered in Seattle, Washington. Allozyne, Inc. operates as a subsidiary of Poniard Pharmaceuticals, Inc.
1600 Fairview Avenue East
Seattle, WA 98102
Founded in 2004
Key Executives for Allozyne, Inc.
Similar Private Companies By Industry
|Synedgen, Inc.||United States|
|CepTor Corporation||United States|
|Cernostics, Inc.||United States|
|MK Stem Cell Inc.||United States|
|Sequus Pharmaceuticals, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Allozyne, Inc., please visit www.allozyne.com. Company data is provided by Capital IQ. Please use this form to report any data issues.